[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-239243-105":53,"doc-detail-239243-en":126},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":119,"head_meta":121,"extra_data":123,"updated_unix":125},105,"en","the-critical-path-for-parkinsons-consortium-understanding-motor-disease-progression-through-quantitative-medicine-poster-modeling-final","The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression through Quantitative Medicine - Poster Modeling Final","","The poster presents the Critical Path for Parkinson’s (CPP) consortium’s quantitative medicine approach to share patient-level data across cohorts and clinical trials in Parkinson disease (PD). It outlines objectives to build and obtain regulatory endorsement of a PD clinical trial enrichment computation tool grounded in a PD progression model. The workflow integrates studies using CDISC standards, harmonizes UPDRS time-course measures via nonlinear mixed-effects regression, evaluates demographic and biomarker covariates, and reports early findings from integrated PPMI and PRECEPT subsets to support optimized trial design for early-stage PD.",{"@graph":63,"@context":118},[64,80,101],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":26,"@type":70,"position":76},"https://docshare.wps.com/template/posters/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/the-critical-path-for-parkinsons-consortium-understanding-motor-disease-progression-through-quantitative-medicine-poster-modeling-final/239243/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/the-critical-path-for-parkinsons-consortium-understanding-motor-disease-progression-through-quantitative-medicine-poster-modeling-final/239243.png","ImageObject",442,249,{"name":88,"@type":89},"\tJames","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-09-18","2026-09-11",true,{"@type":98,"interactionType":99,"userInteractionCount":9},"InteractionCounter",{"@type":100},"ViewAction",{"@type":102,"mainEntity":103},"FAQPage",[104,110,114],{"name":105,"@type":106,"acceptedAnswer":107},"What is the main goal of the CPP poster’s proposed tool for PD clinical trials?","Question",{"text":108,"@type":109},"Develop and obtain regulatory endorsement of a computation tool for PD clinical trial enrichment, based on a PD progression model to inform entry criteria, enrichment strategies, and stratification approaches.","Answer",{"name":111,"@type":106,"acceptedAnswer":112},"How are selected PD studies integrated for the quantitative analysis?",{"text":113,"@type":109},"The poster states that PD clinical data are integrated using PD CDISC standards, building a unique database that consolidates cohorts and trials at the selected stage.",{"name":115,"@type":106,"acceptedAnswer":116},"What modeling approach is used for UPDRS progression measures?",{"text":117,"@type":109},"The time course of harmonized UPDRS parts II and III (including MDS-UPDRS) is described using a nonlinear mixed-effects regression framework with demographic, genetic, biomarker, and clinical covariates.","https://schema.org",{"og:url":78,"og:type":120,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":122,"canonical":78},"index,follow",{"doc_id":124,"site_id":56},239243,1789145865,{"code":4,"msg":5,"data":127},{"doc_id":124,"user_id":128,"nickname":88,"user_avatar":129,"doc_module":9,"category_id":25,"category_name":26,"doc_title":59,"doc_description":61,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":9,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":9,"language":135,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":136,"faqs":137,"seo_title":138,"seo_description":61,"update_tm":125,"read_time":4},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","1402  \nThe Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression  \nthrough Quantitative Medicine  \non behalf of the Critical Path for Parkinson’s (CPP) Consortium  \nKlaus Romero 1, Daniela J. Conrado 1, Brian Corrigan 2 , Kuenhi Tsai 3, Malidi Ahamadi 3, Sreeraj Macha4, Vikram Sinha4, Ian Watson 5, Massimo Bani 6, Pierandrea Muglia 6, Volker D. Kern 1, Caroline H. Williams-Gray7, Donald G. Grosset 8, Michele Hu 9, David Burn 10, Rachael Lawson 10, *Kenneth Marek 11, Arthur Roach 12, Diane Stephenson 1 and Timothy Nicholas 2  \n1 Critical Path Institute, 2 Pfizer Inc., 3 Merck & Co. Inc., North Wales, PA, 4 Merck & Co. Inc., Kenilworth, PA, 5 Lilly, 6 UCB Pharma, 7 University of Cambridge, 8 University of Glasgow, 9 University  \nof Oxford, 10 Newcastle University, 11 Institute for Neurodegenerative Disorders, Molecular NeuroImaging LLC, 12 Parkinson’s UK  \nBackground Methods Results  \nThe Critical Path for Parkinson’s (CPP) consortium (Figure 1) is based on the value of sharing patient-level data from cohorts and clinical trials in Parkinson disease (PD), and transforming those data into generalizable and applicable knowledge for PD therapeutics (Figure 2) .  \nFigure 1  \nCritical Path for Parkinson’s consortium members  \nFigure 2  \nCPP as an expanded data sharing initiative (adapted from Reference 1)  \nObjective  \n• The goal herein is to develop and obtain regulatory endorsement of a computation tool for PD clinical trial enrichment.  \n• This tool will be based on a PD progression model and will inform entry criteria, enrichment strategies and stratification approaches.  \nStudies: Selected studies herein are the Parkinson’s Progression Markers Initiative (PPMI), the Parkinson Research Examination of CEP-1347 Trial (PRECEPT), Oxford PD Centre (OPDC) Discovery Cohort; the Cambridgeshire Parkinson's Incidence from GP to Neurologist cohort (CamPaIGN); Incidence of Cognitive Impairment in Cohorts with Longitudinal Evaluation – PD (ICICLE-PD) and Tracking Parkinson’s (the PRoBaND study)(Figure 3) .  \nData integration: The PD Clinical Data Interchange Standards Consortium (CDISC) standards will enable the integration of the studies in a unique database.  \nModel: The time course of the harmonized parts II and III of the Unified Parkinson’s Disease Rating Scale (UPDRS) and MDS-UPDRS will be described using a non-linear mixedeffects regression.  \nCovariates: Subjects’ demographic, genetic, biomarker and clinical characteristics to be tested as predictors of disease severity at baseline and/or intrinsic rate of disease progression are presented on Figure 4 .  \nFigure 3  \nOverarching CPP Roadmap to Build Quantitative Drug Development Tools  \nSelected studies at the current stage are PPMI, PRECEPT, OPDC, CamPaIGN, ICICLE-PD, and Tracking Parkinson’s (adapted from Reference 2)  \nFigure 4  \nExamples of subject’s characteristics to be tested as predictors of motor impairment in subjects with Parkinson  \n• Up to this moment, patient-level data of PPMI, PRECEPT and CamPaIGN have been integrated using PD CDISC standard. Integration of ICICLE-PD, OPDC and the Tracking Parkinson’s study will follow.  \n• The CPP integrated global database will result in a total of > 6000 subjects into a unified database. Such database will expand the understanding of PD progression and allow a comprehensive investigation of subjects characteristics that predict of disease severity and/or rate of disease progression.  \n• An analysis of integrated subset – PRECEPT (n=191) and PPMI (n=481)– demonstrated that subjects defined as SWEDD (scans without evidence of dopamine transporter deficiency) have an average linear monthly progression in the harmonized motor scores that is 0 .05 (90% CI: -0 .04, 0 . 13) point/month or 0 . 13 point/month lower than that in subjects with dopamine transporter deficit (0 . 18 point/month; 90% CI: 0 . 14, 0 . 21) (Figure 5) . The work herein will provide a comprehensive evaluation of the findings in the presence o","cbCaiqPlTKKGBfYM","https://ap.wps.com/l/cbCaiqPlTKKGBfYM","pdf",2143539,"English","# Background\n## Objective\n## Studies and Data Integration\n## Model and Covariates\n## Results\n## Conclusion\n## References\n## Acknowledgments","[{\"question\":\"What is the main goal of the CPP poster’s proposed tool for PD clinical trials?\",\"answer\":\"Develop and obtain regulatory endorsement of a computation tool for PD clinical trial enrichment, based on a PD progression model to inform entry criteria, enrichment strategies, and stratification approaches.\"},{\"question\":\"How are selected PD studies integrated for the quantitative analysis?\",\"answer\":\"The poster states that PD clinical data are integrated using PD CDISC standards, building a unique database that consolidates cohorts and trials at the selected stage.\"},{\"question\":\"What modeling approach is used for UPDRS progression measures?\",\"answer\":\"The time course of harmonized UPDRS parts II and III (including MDS-UPDRS) is described using a nonlinear mixed-effects regression framework with demographic, genetic, biomarker, and clinical covariates.\"}]","The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression through Quantitative Medicine - Poster Modeling Final | PDF"]